DrugPatentWatch Database Preview
Litigation Details for In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)
» See Plans and Pricing
In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)
| Docket | Start Trial | Date Filed | 2019-03-18 |
| Court | District Court, N.D. Illinois | Date Terminated | 2020-06-30 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Manish Suresh Shah |
| Jury Demand | Both | Referred To | |
| Parties | UFCW LOCAL 1500 WELFARE FUND | ||
| Patents | 7,820,799; 8,093,045; 8,663,945; 8,911,964; 8,926,975; 8,961,973; 8,986,693; 9,018,361; 9,067,992; 9,085,619; 9,090,689; 9,090,867; 9,096,666; 9,187,559; 9,255,143; 9,266,949; 9,359,434; 9,365,645; 9,512,216 | ||
| Attorneys | David C. Giardina | ||
| Firms | Freed Kanner London Millen LLC | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in In Re: Humira (Adalimumab) Antitrust Litigation
The biologic drugs covered by the patents cited in this case are Start Trial and Start Trial .
Details for In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-08-09 | 109 | Amended Complaint | in light of U.S. Patent No. 5,429,746 and a publication of U.S. Patent No. 7,820,799. Although it does…second patent not patentably distinct from claims in a first patent.”19 57. Patent prosecutions…another of 20 patents or patent applications. 131. The patent applications and patents fall roughly…’044 patent, the ’322 patent, and the ’491 patent in the U.K. Yet, as it did with the ’656 patent, prior…of AbbVie’s use patents and found three patents invalid due to obviousness: U.S. Patent No. 8,889,135; | External link to document |
| 2019-10-11 | 124 | Office. Compl. at 41; id. ¶¶ 114-20 (U.S. Patent Nos. 8,093,045; 8,911,964; 9,090,867; and 9,018,361). But… the United States Patent Office has granted, dozens of U.S. patents. The Patent Office has recognized…AbbVie’s patents, several biosimilar companies challenged the patents by petitioning the Patent Trial and…included two overlapping patents, AbbVie sued Amgen for patent infringement on 10 patents, including one for…adalimumab patents, including patents that expire after 2023. If even a single valid patent claim would | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
